Active Recombinant Mouse Ltbr Protein, Fc-tagged

• Cat.No.: Ltbr-1219M
• Product Overview: Recombinant Mouse Ltbr Protein is produced by HEK293 and the target gene encoding Ser28-Pro218 is expressed with a human IgG1 Fc tag at the C-terminus.

Specification

• Source: HEK293
• Species: Mouse
• Tag: Fc
• Form: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
• Bio-activity: Loaded Mouse LTBR-Fc(Cat#CX78) on Protein A Biosensor, can bind Human LIGHT-His(Cat#CM84) with an affinity constant of 0.81 nM as determined in BLI assay. (Regularly tested)
• Molecular Mass: 61 KDa, reducing conditions
• Protein Length: Ser28-Pro218
• Endotoxin: Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
• Storage: Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.
  Reconstituted protein solution can be stored at 2-8°C for 2-7 days.
  Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
• Reconstitution: Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
  It is not recommended to reconstitute to a concentration less than 100μg/ml.
  Dissolve the lyophilized protein in distilled water.
  Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

Gene Information

• Gene Name: Ltbr lymphotoxin B receptor [ Mus musculus ]
• Official Symbol: Ltbr
• Synonyms: LTBR; lymphotoxin B receptor; tumor necrosis factor receptor superfamily member 3; LT beta-R; LT-beta receptor; lymphotoxin-beta receptor; TNF receptor-related protein; tumor necrosis factor receptor superfamily, member 3; CD18; Ltar; TNFCR; Tnfbr; TNFRrp; LTbetaR; TNFR-RP; Tnfrsf3; AI256028; TNFR2-RP; TNF-R-III
• Gene ID: 17000
• mRNA Refseq: NM_010736
• Protein Refseq: NP_034866

Reviews

04/20/2020

Unrivaled in efficiency, this innovative elixir leaves me awestruck.

12/31/2019

By using this reagent, I can better investigate protein interactions.

02/09/2018

The interpretation of the results provided by this reagent is clear, allowing me to better understand the experimental outcomes.

Q&As

What therapeutic strategies can be employed to target LTBR?

Therapeutic strategies targeting LTBR include inhibition of its signaling pathways, modulation of immune response, and anti-cancer approaches. Inhibitors of the NF-κB pathway, such as small molecule inhibitors or neutralizing antibodies, can be used to block LTBR-mediated signaling and reduce inflammation or tumor growth.

What is the current research focus regarding the role of LTBR in disease mechanisms?

Current research on LTBR aims to further elucidate its role in disease mechanisms, particularly in autoimmune disorders, chronic inflammation, and cancer. Studies are investigating the downstream effects of LTBR activation, its involvement in immune cell function, and the identification of potential therapeutic targets within the LTBR signaling pathway.

How is the expression of LTBR regulated at the transcriptional level?

The expression of LTBR is regulated by transcription factors and signaling pathways. For example, NF-κB and AP-1 transcription factors can bind to the promoter region of LTBR gene and enhance its expression. Additionally, cytokines and growth factors can also influence LTBR expression through downstream signaling cascades.

How does the LTBR signaling pathway interact with other signaling pathways?

The LTBR signaling pathway interacts with various other signaling pathways, including those activated by TNFR1, TNFR2, and CD40. These interactions can lead to crosstalk and amplification of signaling, resulting in enhanced cellular responses. Understanding these interactions is crucial for elucidating the complex network of signaling events involved in disease pathogenesis.

What is the biological function of LTBR and its involvement in cellular processes?

LTBR, a membrane protein belonging to the tumor necrosis factor receptor superfamily, regulates various cellular processes such as inflammation, immune response, and lymphoid organ development. It activates signaling pathways including the NF-κB pathway and non-canonical NF-κB pathway.

Are there any genetic variants associated with LTBR expression and disease susceptibility?

Yes, certain genetic variants have been identified that are associated with altered LTBR expression and disease susceptibility. These variants can affect the binding of transcription factors or alter the stability of LTBR mRNA, leading to dysregulation of LTBR expression and increased risk of certain diseases.

What are the potential future directions in LTBR research?

Future research directions in LTBR include exploring the molecular mechanisms underlying LTBR-mediated signaling, investigating the impact of LTBR genetic variants on disease susceptibility, and developing novel therapeutic strategies targeting LTBR. Additionally, studying the interplay between LTBR and other signaling pathways may uncover new insights into disease pathogenesis and identify new therapeutic avenues.